Case Report

A Rare Localized Pituitary Stalk Germinoma Presenting in the Third Decade

Alex González Bóssolo 1, Michelle Mangual Garcia 1, Kyrmarie Davila 1, Ricardo Brau 2, Javier Sanchez Ortiz 3, and Jose Hernan Martinez 1

1 Section of Medicine, Endocrinology, Department of Diabetes and Metabolism, San Juan City Hospital, San Juan, Puerto Rico, USA
2 Section of Neurosurgery, Department of Surgery, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA
3 Pathology Department, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, USA

Correspondence should be addressed to Alex González Bóssolo; alex.gonzalez7@upr.edu

Received 7 April 2018; Accepted 16 August 2018; Published 17 December 2018

We report the case of a 34-year-old male Hispanic patient who presented with an 8-month history of polyuria and decreased libido. An evaluation revealed hypopituitarism, central diabetes insipidus, and a pituitary stalk lesion. No evidence of a neoplasm or an inflammatory/infiltrative disease was found. We treated the patient conservatively with steroid therapy. However, as a result of disease progression, transsphenoidal surgery was performed to obtain tissue for a pathological analysis. Histopathology revealed an intrasellar germinoma, confirmed by immunochemistry. Due to localized disease, radiotherapy was initiated and clinical improvement was noted. This case emphasizes the importance of histopathological analysis; for many physicians, the presentation of a pituitary stalk lesion in a young male adult creates a clinical conundrum. Although the most common etiologies are an inflammatory or secondary neoplasm, the possible presence of an intrasellar neoplasm should not be ruled out. In many cases, imaging characteristics and tumor markers may aid in the diagnosis without the need of an aggressive diagnostic approach. However, in this case, histopathological analysis was the only way to make a correct diagnosis and provide adequate treatment for the patient.

1. Introduction

Germ cell tumors are common neoplasms that occur within the pediatric population. A failure in cell migration to the genital crest can lead to an extragonadal presentation [1]. While the most common central nervous system (CNS) site for germ cell tumor growth is the pineal gland [1], growth in a patient’s third decade of life and an intrasellar presentation are both unconventional features [2]. We present the unique case of a 34-year-old man with pituitary stalk inflammation, secondary to a germ cell tumor.

2. Case Presentation

A 34-year-old man without a previous medical history was referred to our endocrinology clinic due to an eight-month history of generalized fatigue, increased thirst, increased urinary frequency and volume, reduced nocturnal erections, and decreased sexual desire. Additionally, he reported a weight loss of 18 kg in six months, dry skin, cold intolerance, and constipation during the same period. He did not report any headaches, vision problems, recent head trauma, use of illegal substances, family history of pituitary diseases, or close contact with anyone sick. At the time of his referral, therapy with cortisone acetate 25 mg twice daily and levothyroxine (LT4) 50 mcg daily had already been initiated by his primary care physician.

At the initial visit, physical examination revealed normal vital signs and a delayed tendon reflex of the deep tendon reflex in the upper/lower extremities. The first set of serum and urine laboratory examination results revealed hypopituitarism, hypogonadotropic hypogonadism,
Table 1: Laboratory values.

| Laboratory Test                        | Results     |
|----------------------------------------|-------------|
| Ferritin (ng/mL)                       | 242.80      |
| Thyroid Stimulating Hormone (µIU/mL)   | 1.44        |
| Free T4 (ng/dL)                        | 0.9         |
| Adrenocorticotropic Hormone (pg/mL)    | 15          |
| Cortisol AM (µg/dL)                    | 2.38        |
| Total Testosterone (ng/dL)             | < 0.10      |
| Urine Volume (mL/24 hours)             | 11225       |
| Urine Creatinine (mg/24 hours)         | 1582.7      |
| ANA test                               | Negative    |
| HIV 1/2 Antigen Antibody Fourth Generation | Nonreactive |
| Prolactin (ng/mL)                      | 12.1        |
| Anti-TPO Microsomal (IU/mL)            | 6.84        |
| Thyroglobulin AB (IU/mL)               | 11.01       |
| Iron - Total Serum µg/dL               | 93          |
| % Sat of Iron                          | 29          |
| Ferritin (ng/mL)                       | 242.80      |
| AST (U/L)                              | 19          |
| ALT (U/L)                              | 9           |
| Alpha-Fetoprotein Tumor Marker (ng/dL) | < 1.3       |
| B-HCG (mIU/mL)                         | < 0.05      |
| Immunoglobulin G Subclass 4 (mg/dL)    | 21.3        |
| Proteinase 3 Antibody                  | < 1.0       |
| Myeloperoxidase Antibody               | < 1.0       |

**B-HCG:** human chorionic gonadotropin, **AST:** aspartate transaminase, **ALT:** alanine transaminase, **TPO:** thyroid peroxidase, and **AB:** antibody.

polyuria, and hypertonic hypernatremia. The first magnetic resonance imaging (MRI) scan showed a right-sided pituitary microadenoma (3 mm). No suprasellar mass or compression of the optic chiasm was noted. Steroid therapy was changed to hydrocortisone 10 mg/5 gm and levothyroxine replacement was optimized by weight. Follow-up serum laboratory and imaging studies were ordered.

A second MRI, one month later, revealed an abnormal thickening of the infundibulum with no evidence of the microadenoma (Figure 1). New laboratory examination results confirmed the previous findings and ruled out the presence of an autoimmune or inflammatory condition (Table 1). Tumor markers for germ cell tumors were negative. A water deprivation test confirmed central diabetes insipidus. A chest X-ray was unremarkable for masses or infiltrative lesions. Testosterone replacement and desmopressin (DDAVP) were added.

Due to nonspecific imaging findings, a negative X-ray, and no evidence of systemic disease, a conservative approach with prednisone was taken. However, six months later, the stalk lesion worsened. At that time, the patient underwent transsphenoidal surgery for a tissue biopsy. The tissue was positive for an intrasellar pituitary germinoma, confirmed by positive human chorionic gonadotropin (hCG) staining, C-kit, and placental alkaline phosphatase (PLAP) (Figure 2). A lumbar MRI scan and a lumbar puncture were negative for metastatic disease. Treatment with whole ventricle brain radiation was started, with subsequent clinical improvement.

3. Discussion

Primary intracranial germ cell tumors are neoplasms that predominantly occur within the pediatric population and account for 0.4-3.4% of primary intracranial tumors [7]. A failure in cell migration to the genital crest can lead to an extragonadal origin [1]. However, the majority of cases occur in the pineal or suprasellar compartment, with a peak incidence between ages 10-21 [8]. The literature on parasellar germinomas in patients over age 30 is scarce and primarily consists of case reports [1, 9]. In literature of patients over the age of 30, males seem to be more affected than females, a finding which aligns with the SEER registry of intracranial germinomas in patients aging 0-29 years old [10]. According to meta-analyses conducted on treatment guidance of intracranial germinomas, this isolated germinoma presentation in a male over 30 years old is practically nonexistent [11–14].

The presentation described in our case creates a clinical challenge for physicians. Our initial concern for this patient was the reported decreased libido and polyuria. These symptoms are common in patients with stalk lesions. In a retrospective cohort, Young et al. described 152 patients with pituitary stalk lesions; in this cohort, hypogonadism was the most common endocrine abnormality, followed by diabetes insipidus [15]. However, clarifying the etiology of the lesion for proper diagnosis and treatment is burdensome. This mainly occurs due to the imaging findings of stalk
thickening. This finding arose due to a lymphohistiocytic inflammation in the cerebrospinal fluid that caused pituitary stalk inflammation [16]. Although some stalk lesion presentations and features might favor some etiologies, most of them are nonspecific; this creates a clinical conundrum [15]. Also other etiologies such as Langerhans cell histiocytosis [LCH] are indiscernible from a germinoma by MRI [17, 18]. Therefore, as in our case initially, the majority of reported cases are treated as lymphocytic hypophysitis [3, 4] (Table 2). Secreted tumor markers, such as alpha-feto protein and hCG, can aid in the diagnosis. Unfortunately, these markers are not always present in the serum or cerebrospinal fluid (CSF) [19]. Our patient’s results were consistent with the study by Seregni et al., in which 33% of the patients with CNS germinoma presented with normal hCG and alpha-feto protein levels in serum and CSF [20].

Our clinical judgment was consistent with the report by Young et al. As the imaging findings were nonspecific, there was no evidence of systematic disease, and normal tumor markers were present, a conservative approach was taken, and the patient was treated with glucocorticoids. However, when progression of the disease with a further enlargement of stalk lesion on MRI was noted six months later, an aggressive procedure was required and subsequently confirmed the diagnosis. Following diagnosis, we were able to administer adequate therapy. As our patient had a localized germinoma, radiotherapy (RT) was highly effective. Studies have shown a 5-year progression-free survival (PFS) rate of more from 88-97% [20]. Although adjuvant chemotherapy has been used to minimize radiotherapy effects, the PFS has lessened in cases of using focal RT rather than whole brain RT [21]. Additionally, the efficacy of chemotherapy alone has been shown to be inferior to that of radiotherapy, with a 44% rate of recurrence at 2.5 years after therapy [22].

In conclusion, the presentation of a pituitary stalk lesion in a young male adult creates a clinical challenge for most physicians. Although the most common presentation is an inflammatory or metastasis, the presence of intrasellar
Table 2: Cases of germinomas with similar clinical features described in the literature.

| Case                          | Age | Sex  | Clinical Feature          | Hormonal Deficiency                        | Stalk Thickening MRI | Treated as LH | Tumors Markers |
|-------------------------------|-----|------|----------------------------|--------------------------------------------|----------------------|--------------|----------------|
| Terasaka et al. (2012) [3]    | 40  | Female | Headache, diplopia         | Hypopituitarism, Central DI                 | Yes                  | Yes          | PLAP           |
| Torremocha et al. (2002) [4]  | 45  | Male   | Headache                   | Gonadotropin deficiencies                   | Yes                  | Yes          | b-hCG [CSF]   |
| Shimizu et al. (2014) [5]     | 36  | Male   | General malaise, decreased libido | Hypopituitarism, Central DI                 | Yes                  | No           | None           |
| Wen-Ping Yang et al. (2017)   | 38  | Male   | General weakness           | Hypopituitarism, Central DI                 | No                   | No           | b-hCG [CSF]   |
| Gonzalez et al. (2018)        | 34  | Male   | Fatigue, decreased libido   | Hypopituitarism, Central DI                 | Yes                  | Yes          | PLAP, C-kit, b-hCG |

PLAP: placental alkaline phosphatase, DI: diabetes insipidus, b-hCG: beta-human chorionic gonadotropin, CSF: cerebrospinal fluid, MRI: magnetic resonance imaging, and LH: lymphocytic hypophysitis.

pathology should not be discarded. A conservative approach should be pursued first, reserving a more aggressive approach for cases with equivocal imaging and biochemical findings. However, in cases similar to ours, a histopathological analysis may be the only way to determine a correct diagnosis and provide adequate treatment for the patient.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors wish to thank Editage® for English language editing. The authors are also grateful to Yolianne Lozada Capriles, MD, for her invaluable advice and discussion regarding the paper. The authors are also grateful to Roman Velez Rosario, MD, for his contribution in the description of the histopathology images. Jose Hernan Martinez is deceased.

References

[1] R. J. Packer, B. H. Cohen, and K. Coney, "Intracranial germ cell tumors," The Oncologist, vol. 5, no. 4, pp. 312–320, 2000.
[2] K. H. Carlos Chung, B. K. Owler, M. Dexter, and R. Chaseling, "Paediatric germ cell tumours of the central nervous system: Results and experience from a tertiary-referral paediatric institution in Australia," Journal of Clinical Neuroscience, vol. 20, no. 4, pp. 514–519, 2013.
[3] S. Terasaka, M. Kawabori, H. Kobayashi et al., "Neurohypophyseal germinoma with abundant fibrous tissue," Brain Tumor Pathology, vol. 29, no. 1, pp. 58–62, 2012.
[4] F. Torremocha, S. Hadijaj, E. Menet et al., "Pituitary germinoma presenting as a pseudotumoral lymphocytic hypophysitis in a man," Annales d’Endocrinologie, vol. 63, no. 1, pp. 13–17, 2002.
[5] K. Shimizu, Y. Mineharu, H. Imamura et al., "Intracranial germinomas in a father and his son," Child’s Nervous System, vol. 30, no. 12, pp. 2433–2466, 2014.
[6] W.-P. Yang, H.-Y. Chien, and Y.-C. Lin, "β-human chorionic gonadotropin-secreting intracranial germ-cell tumor associated with high testosterone in an adult man: A case report," Oncology Letters, vol. 14, no. 1, pp. 1129–1132, 2017.
[7] H. J. Hoffman, H. Otsubo, E. B. Hendrick et al., "Intracranial germ-cell tumors in children," Journal of Neurosurgery, vol. 74, no. 4, pp. 545–551, 1991.
[8] R. S. Arora, R. D. Alston, T. O. B. Eden, M. Geraci, and J. M. Birch, "Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003," Cancer, vol. 118, no. 17, pp. 4290–4297, 2012.
[9] B. J. McCarthy, S. Shibui, T. Kayama et al., "Primary CNS germ cell tumors in Japan and the United States: An analysis of 4 tumor registries," Neuro-Oncology, vol. 14, no. 9, pp. 1194–1200, 2012.
[10] J. N. Poynter, R. Fonstad, J. Tolar, L. G. Spector, and J. A. Ross, "Incidence of intracranial germ cell tumors by race in the United States, 1992–2010," Journal of Neuro-Oncology, vol. 120, no. 2, pp. 381–388, 2014.
[11] S. J. Huh, K. H. Shin, I. H. Kim, Y. C. Ahn, S. W. Ha, and C. I. Park, "Radiotherapy of intracranial germinomas," Radiotherapy & Oncology, vol. 38, no. 1, pp. 19–23, 1996.
[12] G. O. Schoenfeld, R. J. Amund, I. M. Schmalfuss et al., "Low-dose prophylactic craniospinal radiotherapy for intracranial germinoma," International Journal of Radiation Oncology, Biology & Physics, vol. 65, no. 2, pp. 481–485, 2006.
[13] H. Fu, X. Guo, R. Li, and B. Xing, "Radiotherapy and chemotherapy plus radiation in the treatment of patients with pure intracranial germinoma: A meta-analysis," Journal of Clinical Neuroscience, vol. 43, pp. 32–38, 2017.
[14] K.-Y. Eom, I. H. Kim, C. I. Park et al., "Upfront Chemotherapy and Involved-Field Radiotherapy Results in More Relapses Than Extended Radiotherapy for Intracranial Germinomas: Modification in Radiotherapy Volume Might Be Needed," International Journal of Radiation Oncology • Biology • Physics, vol. 71, no. 3, pp. 667–671, 2008.
[15] A. F. Turcu, B. J. Erickson, E. Lin et al., "Pituitary stalk lesions: The Mayo clinic experience," The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 5, pp. 1812–1818, 2013.
[16] N. Ozbey, A. Sencer, S. Tanyolac et al., "An intrasellar germinoma with normal cerebrospinal fluid beta-HCG concentrations misdiagnosed as hypophysitis," Hormones, vol. 5, no. 1, pp. 67–71, 2006.
[17] D. Radojkovic, M. Pesic, D. Dimic et al., "Localised Langerhans cell histiocytosis of the hypothalamic-pituitary region: case report and literature review," *Hormones*, vol. 17, no. 1, pp. 119–125, 2018.

[18] A. Isoo, K. Ueki, T. Ishida et al., "Langerhans Cell Histiocytosis Limited to the Pituitary-Hypothalamic Axis. Two Case Reports," *Neuroligia medico-chirurgica*, vol. 40, no. 10, pp. 532–535, 2000.

[19] M. F. Guzzo, C. B. F. Bueno, T. T. Amancio et al., "An intrasellar germinoma with normal tumor marker concentrations mimicking primary lymphocytic hypophysitis," *Arquivos Brasileiros de Endocrinologia & Metabologia*, vol. 57, no. 7, pp. 566–570, 2013.

[20] A. W. Jensen, N. N. Issa Laack, J. C. Buckner, P. J. Schomberg, C. J. Wetmore, and P. D. Brown, "Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma," *International Journal of Radiation Oncology ∙ Biology ∙ Physics*, vol. 77, no. 5, pp. 1449–1456, 2010.

[21] G. Calaminus, R. Kortmann, J. Worch et al., "SIOP CNS GCT 96: Final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease," *Neuro-Oncology*, vol. 15, no. 6, pp. 788–796, 2013.

[22] N. S. Da Silva, A. M. Cappellano, B. Diez et al., "Primary chemotherapy for intracranial germ cell tumors: Results of the third international CNS germ cell tumor study," *Pediatric Blood & Cancer*, vol. 54, no. 3, pp. 377–383, 2010.